Abstract 185P
Background
The impact of etiology on response to immunotherapy in advanced hepatocellular carcinoma (HCC) is being extensively debated. Early clinical trials suggested that PD-1/PD-L1 blockade prolonged survival of viral HCC patients, but not of those with non-viral HCC. However, a recent post-hoc analysis of the IMbrave-150 trial showed atezolizumab plus bevacizumab (AB) to exhibit similar efficacy in viral and non-viral groups. Here we investigated the role of etiology in AB-treated HCC patients in a real-world scenario to consolidate these findings and integrate them with previous comparative studies with lenvatinib.
Methods
We retrospectively analyzed 885 HCC patients treated with first-line AB from Eastern and Western countries, 53.9% having viral and 46.1% non-viral etiology. Baseline clinical and laboratory characteristics were analyzed with uni- and multi-variate models to assess the impact of etiology on overall survival (OS), time to progression (TTP), response rates and to identify prognostic factors in etiology subgroups.
Results
Overall, no statistically significant differences were found in OS (mOS: viral 15.9mo; non-viral 16.3mo), TTP (mTTP: viral 8.3mo; non-viral 7.2mo), and response rates based on etiology. However, certain prognostic factors differed between the two groups. Among patients with viral etiology, eosinophil count positively correlated with OS, while among non-viral patients AST and ALP levels were significantly related to OS. AFP, NLR, and ALBI score were prognostic for both groups. The toxicity profile of AB almost overlaps in the two etiology subgroups.
Conclusions
These findings indicate that underlying etiology does not significantly impact the outcome of HCC patients treated with AB. However, some prognostic factors differ between viral and non-viral patients, with immunological factors being mostly related to the former while metabolic to the latter, supporting potential biological differences. This may also account for different outcomes of AB observed in comparative studies with lenvatinib in etiology subgroups. Prospective and comparative trials stratifying by etiology are warranted to validate these findings and guide clinical practice.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
F. Finkelmeier: Financial Interests, Personal, Speaker, Consultant, Advisor: AbbVie, MSD, Ipsen, Esai and Fresenius. M. Scartozzi: Financial Interests, Personal, Speaker, Consultant, Advisor: Amgen, MSD, Merck, BMS, Servier, Eisai, GSK. A. Casadei Gardini: Financial Interests, Personal, Speaker, Consultant, Advisor: MSD, Eisai, Bayer, Bristol Myers Squibb, AstraZeneca and GSK. All other authors have declared no conflicts of interest.
Resources from the same session
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract
297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?
Presenter: Charity Kotambunan
Session: Poster Display
Resources:
Abstract